Core Viewpoint - Insmed's stock price increased by 5.5% to $153.32, influenced by significant trading volume and positive data from a competitor's study on a similar treatment for idiopathic pulmonary fibrosis (IPF) [1][2]. Group 1: Company Developments - Insmed is developing treprostinil palmitil inhalation powder (TPIP), a prodrug version of treprostinil, which allows for once-daily dosing compared to the multiple doses required for United Therapeutics' Tyvaso [3]. - The company is on track to initiate a late-stage study for TPIP in IPF in the second half of 2026 [3]. Group 2: Market Response and Financial Expectations - The positive data from United Therapeutics' study, which showed a significant improvement in forced vital capacity (FVC) in IPF patients, indirectly supports the therapeutic potential of treprostinil [2][4]. - Insmed is expected to report a quarterly loss of $1.00 per share, reflecting a year-over-year increase of 29.6%, with revenues projected at $299.57 million, a 222.7% increase from the previous year [5]. Group 3: Earnings Estimates and Stock Performance - The consensus EPS estimate for Insmed has been revised slightly higher in the last 30 days, indicating a potential for price appreciation [6][7]. - Insmed currently holds a Zacks Rank of 3 (Hold), while Keros Therapeutics, a competitor, has seen a significant negative revision in its EPS estimate [7][8].

Core Viewpoint - Marex Group PLC (MRX) has shown a significant increase in share price, rising 5.9% to $42.96, following a period of decline, indicating potential recovery and investor interest [1] Group 1: Business Performance - Marex has maintained a rally for five consecutive days, attributed to its diversified business model across commodities, financial markets, and investment solutions, which allows it to generate revenue from various sources and market cycles [2] - The company expects first-quarter 2026 revenues to be between $667 million and $697 million, a substantial increase from $467 million in the first quarter of 2025, with adjusted profit before tax projected at $140 million to $150 million compared to $96 million a year earlier [3] Group 2: Earnings Expectations - The upcoming quarterly earnings report is anticipated to show earnings of $1.05 per share, reflecting a year-over-year increase of 15.4%, with revenues expected to reach $529 million, up 13.2% from the same quarter last year [4] - However, the consensus EPS estimate for the quarter has been revised 2% lower over the last 30 days, which may indicate a negative trend in earnings estimate revisions that could affect future stock price movements [5] Group 3: Market Position - Marex Group PLC holds a Zacks Rank of 3 (Hold), indicating a neutral outlook, while another company in the same industry, MidCap Financial Investment (MFIC), has a similar rank and has experienced a 2.3% decline in its last trading session [6] - MidCap Financial's consensus EPS estimate has changed by +0.9% over the past month, but it still represents a decrease of 2.7% from the previous year [7]

Company Overview - Kingsoft Cloud Holdings Limited Sponsored ADR (KC) shares increased by 19% to $14.27 in the last trading session, following a significant trading volume, contrasting with a 7.3% loss over the previous four weeks [1] - The company benefits from advancements in AI and Intelligent Cloud, as well as Public Cloud and Enterprise Cloud Services, leveraging the Xiaomi and Kingsoft ecosystem for technology and product development [1] Financial Performance - Kingsoft Cloud is projected to report a quarterly loss of $0.07 per share, reflecting a year-over-year decline of 75%, while revenues are expected to reach $378.12 million, marking a 23.7% increase from the same quarter last year [2] - The consensus EPS estimate for Kingsoft Cloud has been revised down by 27.3% over the last 30 days, indicating a negative trend in earnings estimate revisions, which typically does not lead to price appreciation [3] Industry Context - Kingsoft Cloud is categorized under the Zacks Internet - Software industry, which includes other companies like Getty Images Holdings, Inc. (GETY), whose stock closed 2.8% lower at $0.82, with a month-to-date return of -28.1% [3] - Getty Images Holdings, Inc. has an unchanged consensus EPS estimate of $0.03 for the upcoming report, representing a 400% increase compared to the previous year's EPS [4]

Core Viewpoint - Analysts expect The Beauty Health Company (SKIN) to report a quarterly loss of -$0.07 per share, reflecting a year-over-year increase of 12.5%, with revenues projected at $78.17 million, down 6.4% from the previous year [1] Financial Projections - The consensus EPS estimate for the upcoming quarter has remained unchanged over the past 30 days, indicating a reassessment of initial projections by covering analysts [1] - Analysts predict 'Delivery Systems Net Sales' to be $20.85 million, representing a year-over-year decline of 22.2% [4] - The average estimate for 'Consumables Net Sales' is $57.34 million, indicating a slight year-over-year increase of 1.1% [4] - 'Geographic Revenue- Americas' is expected to reach $53.65 million, reflecting a decrease of 6% from the year-ago quarter [4] - 'Geographic Revenue- EMEA' is projected at $17.20 million, while 'Geographic Revenue- Asia Pacific (APAC)' is expected to be $7.49 million, showing a year-over-year decline of 18.6% [5] Market Performance - Shares of Beauty Health have decreased by 10.9% over the past month, contrasting with a 2.7% decline in the Zacks S&P 500 composite [5] - The company holds a Zacks Rank 4 (Sell), suggesting it is expected to underperform the overall market in the near future [5]

Core Insights - Analysts expect CubeSmart (CUBE) to report quarterly earnings of $0.66 per share, reflecting a year-over-year decline of 2.9% [1] - Revenue projections stand at $280.47 million, indicating a 21.2% increase from the same quarter last year [1] - The consensus EPS estimate has remained unchanged over the past 30 days, suggesting analysts have reassessed their initial projections [1] Earnings Projections - Analysts forecast 'Property management fee income' to reach $10.16 million, showing a year-over-year decline of 2.2% [4] - 'Rental income' is estimated at $244.19 million, representing a 7% increase from the previous year [4] - 'Other property related income' is expected to be $30.87 million, indicating a year-over-year growth of 6.1% [4] Additional Metrics - The average prediction for 'Depreciation and amortization' is set at $67.16 million [5] - CubeSmart shares have increased by 5.3% over the past month, contrasting with a -1% change in the Zacks S&P 500 composite [5] - CubeSmart holds a Zacks Rank 4 (Sell), suggesting it may underperform the overall market in the near term [5]

Group 1 - Analysts expect C3.ai, Inc. (AI) to report a quarterly loss of -$0.29 per share, reflecting a year-over-year decline of 141.7% [1] - Revenue is projected to be $75.82 million, down 23.2% from the same quarter last year [1] - There has been no revision in the consensus EPS estimate over the past 30 days, indicating a stable outlook among analysts [1] Group 2 - The estimated revenue from Professional services is $7.48 million, indicating a year-over-year decline of 42.9% [4] - Analysts project Subscription revenue to be $68.32 million, reflecting a decrease of 20.3% from the previous year [4] - The estimated Gross margin for Professional services is 74.1%, down from 80.0% year-over-year [4] Group 3 - The average prediction for Gross margin in Subscription is 49.9%, compared to 56.0% in the same quarter last year [5] - C3.ai shares have decreased by 17.5% in the past month, contrasting with the Zacks S&P 500 composite's decline of 0.8% [5] - C3.ai holds a Zacks Rank of 4 (Sell), indicating expected underperformance relative to the overall market [5]

Core Viewpoint - Wall Street analysts anticipate a decline in UFP Industries' quarterly earnings and revenues, indicating potential challenges for the company in the upcoming report [1]. Group 1: Earnings and Revenue Projections - Analysts expect UFP Industries to report earnings of $1.03 per share, reflecting a year-over-year decline of 14.2% [1]. - Revenue projections stand at $1.4 billion, which is a decrease of 4% compared to the same quarter last year [1]. - The consensus EPS estimate has remained unchanged over the past 30 days, indicating a stable outlook among analysts [1]. Group 2: Key Metrics Estimates - 'Net Sales- Retail' is projected to reach $509.03 million, suggesting a year-over-year change of -3% [4]. - 'Net Sales- Construction' is estimated at $457.57 million, indicating a decline of 6% year over year [4]. - 'Net Sales- Packaging' is expected to be $362.03 million, reflecting a change of -3.5% from the previous year [4]. Group 3: Market Performance - UFP Industries' shares have shown a return of +5.9% over the past month, outperforming the Zacks S&P 500 composite, which declined by -1.3% [4]. - The company holds a Zacks Rank 2 (Buy), suggesting expectations of better performance compared to the overall market in the near future [4].

Core Insights - Medtronic (MDT) is expected to report quarterly earnings of $1.33 per share, a decline of 4.3% year-over-year, with revenues projected at $8.9 billion, reflecting a 7.3% increase compared to the previous year [1] Revenue Estimates - Analysts estimate 'Net Sales- World Wide Revenue- Cardiovascular' to be $3.37 billion, indicating a year-over-year increase of 10.8% [4] - 'Net Sales- World Wide Revenue- Neuroscience' is projected to reach $2.59 billion, reflecting a 5.3% increase year-over-year [4] - 'Net Sales- World Wide Revenue- Neuroscience- Cranial & Spinal Technologies' is expected to be $1.32 billion, a 6% increase from the prior year [5] - 'Net Sales- World Wide Revenue- Neuroscience- Neuromodulation' is forecasted at $505.68 million, indicating a 6.2% year-over-year change [5] U.S. Revenue Estimates - 'Net Sales- U.S. Revenue' is anticipated to be $4.53 billion, suggesting a 6.9% increase year-over-year [6] - 'Net Sales- U.S. Revenue- Neuroscience- Neuromodulation' is projected at $342.56 million, reflecting a 4.8% increase [6] International Revenue Estimates - 'Net Sales- ROW- Neuroscience- Cranial & Spinal Technologies' is expected to reach $338.62 million, indicating a 10.3% year-over-year change [6] - 'Net Sales- ROW- Neuroscience- Specialty Therapies' is projected at $335.35 million, reflecting a 7.1% increase [7] - 'Net Sales- ROW- Cardiovascular- Cardiac Rhythm & Heart Failure' is expected to be $826.64 million, indicating a 7.4% increase [8] - 'Net Sales- ROW- Diabetes' is projected at $522.47 million, reflecting a significant 14.3% increase from the previous year [8] - The consensus estimate for 'Net Sales- ROW- Cardiovascular' stands at $1.77 billion, indicating an 8.5% year-over-year change [8] Stock Performance - Medtronic shares have shown a return of +5.2% over the past month, outperforming the Zacks S&P 500 composite, which has seen a -0.3% change [9]

Core Insights - MKS (MKSI) is expected to report quarterly earnings of $2.51 per share, reflecting a 16.7% increase year-over-year, with revenues projected at $1.03 billion, a 10.2% increase compared to the previous year [1] Revenue Estimates - Analysts project 'Net Revenues- Semiconductor' to reach $421.37 million, indicating a 5.3% increase from the prior-year quarter [4] - 'Net Revenues- Specialty Industrial' is expected to be $285.23 million, showing a 1.5% increase year-over-year [4] - 'Net Revenues- Electronics and Packaging' is estimated at $298.92 million, reflecting a 17.7% year-over-year change [4] - 'Net Revenues- Products' is forecasted to be $866.43 million, indicating a 5.2% increase from the previous year [5] - 'Net Revenues- MSD (Materials Solutions Division)' is expected to reach $327.51 million, showing a 9.2% increase year-over-year [5] - 'Net Revenues- PSD (Photonics Solutions Division)' is projected at $266.08 million, reflecting a 1.6% increase from the prior year [6] - 'Net Revenues- Services' is forecasted to be $126.87 million, indicating a 14.3% year-over-year change [6] - 'Net Revenues- VSD (Vacuum Solutions Division)' is estimated at $399.70 million, reflecting a 7.5% increase year-over-year [6] Stock Performance - MKS shares have increased by 30.7% in the past month, contrasting with the Zacks S&P 500 composite's decline of 0.3%, indicating strong market performance [6] - MKS holds a Zacks Rank 1 (Strong Buy), suggesting it is expected to outperform the overall market in the near term [6]

Core Insights - Telus is expected to report quarterly earnings of $0.18 per share, unchanged from the same period last year, with revenues projected at $3.93 billion, reflecting a year-over-year increase of 2.2% [1] - There have been no revisions in the consensus EPS estimate over the last 30 days, indicating stability in analysts' forecasts [1][2] Financial Metrics - Total telecom subscriber connections are projected to reach 21.02 million, up from 20.18 million in the same quarter last year [4] - Subscribers for connected devices are expected to be 4.30 million, compared to 3.73 million a year ago [4] - Internet subscribers are estimated at 2.81 million, slightly up from 2.76 million in the previous year [5] - TV subscribers are forecasted to reach 1.45 million, an increase from 1.39 million year-over-year [5] - Security subscribers are estimated at 1.16 million, up from 1.12 million in the same quarter last year [6] - Residential voice subscribers are projected to be 977.06 thousand, down from 1.03 million a year ago [6] - Mobile phone subscribers are expected to be 10.33 million, compared to 10.15 million in the same quarter last year [7] Market Performance - Telus shares have returned +5.6% over the past month, outperforming the Zacks S&P 500 composite, which showed no change [7] - The company holds a Zacks Rank 2 (Buy), indicating expectations of beating overall market performance in the near future [7]